<DOC>
	<DOCNO>NCT01463410</DOCNO>
	<brief_summary>This clinical study demonstrate accuracy chromosomal aberration gene mutation marker AMLProfiler molecular diagnostic assay generate clinical performance data support Pre-Market Approval ( PMA ) submission Food Drug Administration vitro diagnostic use within United States America . The objective demonstrate positive negative percent agreement marker compare AMLProfiler result multiple clinical participate site data generate use laboratory develop bi-directional sequencing method generate molecular diagnostic reference lab . The AMLProfiler assay qualitative vitro diagnostic test detection AML APL specific chromosomal aberration ( specific recurrent translocation inversion ) , well expression specific genetic marker RNA extract bone marrow aspirate patient Acute Myeloid Leukemia .</brief_summary>
	<brief_title>Accuracy Testing Chromosomal Aberration Gene Mutation Markers AMLProfiler</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Chromosome Aberrations</mesh_term>
	<mesh_term>Chromosome Disorders</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<criteria>1 . Subjects cytopathologically confirm diagnosis AML subject refractory anemia excess blast ( RAEB ) accord WHO 2008 classification 2 . â‰¥ 18 year 3 . Written inform consent 1 . Subjects without cytopathologically confirm diagnosis AML subject refractory anemia excess blast ( RAEB ) accord WHO 2008 classification 2 . &lt; 18 year 3 . Without write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>